查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466688

基因治疗市场：按类型、载体类型、应用划分 - 2024-2030 年全球预测

Gene Therapy Market by Type (Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy), Vector Type (Non-viral Vectors, Viral Vectors), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年基因治疗市场规模为56.7亿美元，预计2024年将达70.5亿美元，2030年将达到304.8亿美元，复合年增长率为27.15%。

基因治疗是一种将遗传物质引入、改变或修饰到个别细胞中以治疗或预防疾病的医疗程序。基因治疗的主要目的是透过替换或修復缺陷基因、引入治疗基因、调节基因表现来解决遗传性疾病。该领域在从根本上治疗各种遗传性和后天性疾病方面具有巨大潜力。有几个因素促进了基因治疗市场的成长，包括慢性病盛行率的增加、基因治疗接受率的提高、临床试验的激增以及製药领域研发支出的增加。然而，这些疗法的成本非常高，并且涉及复杂且漫长的开发过程。此外，对脱靶效应、免疫抗原性和长期安全性的担忧可能会阻碍市场需求。同时，先进技术的发展正在开闢基因编辑和治疗领域几个以前无法进入的前沿领域。由于监管机构越来越多地核准基因治疗产品，基因治疗市场预计将进一步成长，为标靶疾病治疗提供许多潜在机会。

主要市场统计
基准年[2023] 56.7亿美元
预测年份 [2024] 70.5亿美元
预测年份 [2030] 304.8亿美元
复合年增长率（%） 27.15%

类型：癌症基因治疗普及

抗原基因治疗涉及将编码特定抗原的基因引入患者的细胞中。目标是刺激免疫系统识别表达这些抗原的细胞并针对它们产生免疫反应。这种方法通常被用于癌症免疫疗法，它鼓励免疫系统瞄准并消除癌细胞。癌症基因疗法旨在透过针对癌细胞的特定方面来治疗或消除癌症。这种治疗方法使用基因编辑技术来纠正与癌症相关的特定基因突变。细胞激素基因疗法涉及将编码特定细胞激素的基因引入患者的细胞中。这种方法旨在透过引入产生免疫刺激细胞激素因子的基因来提高免疫系统识别和消除癌细胞的能力。自杀基因疗法，也称为基因定向酶前驱药物疗法（GDEPT），涉及将编码酶的基因引入目标细胞。基因产生的酵素活化前驱药物（无毒物质）并选择性地将它们转化为目标细胞内的有毒药物。这种方法常用于癌症治疗以诱导癌细胞凋亡。抑癌基因治疗的重点是恢復或增强抑癌基因的功能。抑癌基因疗法旨在替代或激活这些基因来控製或抑制癌细胞的生长。

载体类型：显着利用病毒载体来提高基因转移到细胞的效率

在基因治疗中，非病毒载体是不涉及病毒的载体或递送系统。这些载体将治疗性遗传物质（例如 DNA 或 RNA）传递至目标细胞以治疗或预防疾病。非病毒载体的优点是在免疫抗原性方面比病毒载体更安全、更容易生产、整合到宿主基因组的风险更低。病毒载体是源自病毒的载体或载体，经过修饰可将治疗性遗传物质传递至目标细胞，作为基因治疗的一部分。这些载体利用病毒进入细胞和传递基因的天然能力，并且设计为安全有效。病毒载体是许多基因治疗策略的关键，因为它们可以有效地将基因传递到细胞中。

应用：基因疗法可作为治疗心血管疾病的创新方法

基因疗法已成为治疗心血管疾病的突破性方法。它主要侧重于将基因引入细胞中以替换、惰性或引入新的遗传物质来治疗或控制心血管疾病。基因治疗的进展为阻止遗传疾病的进展提供了一条有前途的治疗途径。基因疗法透过解决导致遗传疾病的潜在遗传异常，在治疗遗传疾病方面具有巨大潜力。基因治疗可以透过多种增强宿主免疫反应、开发抗病毒药物和直接针对传染源的策略，在对抗感染疾病方面发挥作用。基因疗法透过解决神经系统疾病背后的遗传和分子异常，有助于治疗神经系统疾病。基因疗法在肿瘤学领域有望治疗各种类型的癌症。肿瘤学基因治疗的目标是针对并纠正导致癌症发生、生长和抗治疗性的遗传因素。

区域洞察

由于基因治疗研究和创新的兴起以及该领域的大量投资，美洲成为一个重要的地区。基因治疗市场正在快速成长，这主要是由于慢性病盛行率的改善、基因研究的资金投入、行业参与者的强大以及 FDA 的核准对基因治疗趋势产生重大影响。欧洲地区凭藉其成熟的製药公司和先进的基因治疗研究，在基因治疗领域显示出可观的成长。欧盟（EU）大力投资医疗保健研究，包括基因治疗。各国在治疗性临床试验方面处于领先地位，特别是在癌症、心血管和遗传疾病方面。亚太地区是基因治疗领域快速新兴的市场。蓬勃发展的生物技术产业和大量政府资助正在推动临床试验的激增，而创新基因疗法研究的快速进展进一步推动了市场需求的成长。总体而言，亚太地区基因治疗的成长是由大量患者数量、不断上升的医疗成本和不断变化的法规环境共同推动的。

FPNV定位矩阵

FPNV定位矩阵对于评估基因治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对基因治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.基因治疗市场的市场规模与预测是多少？

2.在基因治疗市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.基因治疗市场的技术趋势和法规结构是什么？

4.基因治疗市场主要厂商的市场占有率是多少？

5.进入基因治疗市场合适的形式和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病盛行率上升，治疗中心数量迅速增加
      • 政府对基因治疗的支持与道德接受
    • 抑制因素
      • 基因治疗相关的高成本
    • 机会
      • 持续研究和开发罕见疾病和基因治疗进展
      • 创新的支付模式和有利的监管核准
    • 任务
      • 新基因疗法的潜在有害影响和道德担忧
  • 市场区隔分析
    • 类型：癌症基因疗法在癌症治疗的普及
    • 载体类型：病毒载体的大量利用提高了基因递送至细胞的效率
    • 应用：基因疗法作为治疗心血管疾病的创新方法的潜在应用
  • 市场趋势分析
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化

第六章 基因治疗市场：依类型

  • 抗原基因治疗
  • 癌症基因治疗
  • 细胞激素基因治疗
  • 自杀基因治疗
  • 抑癌基因治疗

第七章基因治疗市场：依载体类型

  • 非病毒载体
  • 病毒载体

第八章基因治疗市场：依应用分类

  • 心血管疾病
  • 遗传疾病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤性疾病

第九章 北美和南美基因治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区基因治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的基因治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争情境分析
    • Charles River 推出 Lentilation 平台以加速基于 LVV 的基因治疗製造
    • Laurus 在印度推出基因治疗资产
    • 蓝鸟生物准备推出基因疗法作为镰状疾病的应用方法

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-437517DB6C62

[196 Pages Report] The Gene Therapy Market size was estimated at USD 5.67 billion in 2023 and expected to reach USD 7.05 billion in 2024, at a CAGR 27.15% to reach USD 30.48 billion by 2030.

Gene therapy is a medical procedure that introduces, alters, or corrects genetic material within an individual's cells to treat or prevent disease. The primary purpose of gene therapy is to address genetic disorders by replacing or repairing faulty genes, introducing therapeutic genes, or regulating the expression of genes. This field holds great promise for treating various genetic and acquired diseases at their root cause. Several factors are contributing to the growth of the gene therapy market, including an increase in the prevalence of chronic conditions, a rise in acceptance of gene therapy treatment, a surge in clinical trials, and escalated R&D expenditure in the pharmaceutical sector. However, the cost of these therapies is exceptionally high, accompanied by a complex and lengthy development process. Additionally, concerns regarding off-target effects, immunogenicity, and long-term safety may hamper its market demand. Moreover, advanced technology development has opened several previously inaccessible gene editing and therapy frontiers. The gene therapy market is anticipated to grow further due to regulatory authorities' rising approval of gene therapy products, which brought forth many potential opportunities with targeted disease treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 5.67 billion
Estimated Year [2024] USD 7.05 billion
Forecast Year [2030] USD 30.48 billion
CAGR (%) 27.15%

Type: Prevalence of cancer gene therapy for cancer treatment

Antigen gene therapy introduces genes that encode specific antigens into a patient's cells. The goal is stimulating the immune system to recognize and mount an immune response against cells expressing these antigens. This approach is often explored in cancer immunotherapy, where the immune system is encouraged to target and eliminate cancer cells. Cancer gene therapy aims to treat or eliminate cancer by targeting specific aspects of cancer cells. This therapy uses gene editing technologies to modify or correct specific genetic mutations associated with cancer. Cytokine gene therapy involves introducing genes encoding specific cytokines into the patient's cells. This approach aims to enhance the immune system's capacity to identify and eliminate cancer cells by introducing genes that produce immune-stimulating cytokines. Suicide gene therapy, also known as gene-directed enzyme prodrug therapy (GDEPT), involves introducing a gene that encodes an enzyme into target cells. The enzyme produced by the gene activates a prodrug (a non-toxic substance), converting it into a toxic drug selectively in the target cells. This approach is often used in cancer therapy to cause apoptosis in cancer cells. Tumor suppressor gene therapy focuses on restoring or enhancing the function of tumor suppressor genes. Tumor suppressor gene therapy aims to either replace or activate these genes to control or inhibit the growth of cancer cells.

Vector Type: Significant utilization of viral vector providing higher efficiency in delivering genes into cells

Non-viral vectors in gene therapy are carriers or delivery systems that do not involve viruses. These vectors transport therapeutic genetic material, such as DNA or RNA, into target cells to treat or prevent diseases. Non-viral vectors are considered safer in terms of immunogenicity than viral vectors and have some advantages in terms of ease of production and reduced risk of integration into the host genome. Viral vectors are vehicles or carriers derived from viruses modified to deliver therapeutic genetic material into target cells as part of gene therapy. These vectors are engineered to be safe and effective, taking advantage of the natural ability of viruses to enter cells and deliver their genetic payload. Viral vectors are key to many gene therapy strategies because they efficiently deliver genes into cells.

Application: Potential adoption of gene therapy as a revolutionary approach to treating cardiovascular diseases

Gene therapy has appeared as a revolutionary method to treating cardiovascular diseases. It mainly focuses on delivering genes to replace, inactivate, or introduce new genetic material to cells to cure or manage cardiovascular illness. Advancements in gene therapy offer promising treatment pathways to hinder the progression of genetic diseases. Gene therapy holds significant promise in treating genetic diseases by addressing the underlying genetic abnormalities that cause these conditions. Gene therapy can play a role in combating infectious diseases through various strategies to enhance the host's immune response, develop antiviral agents, or directly target the infectious agent. Gene therapy holds promise for treating neurological diseases by addressing the underlying genetic and molecular abnormalities associated with these disorders. Gene therapy holds promise in oncology for treating various types of cancer. The goal of gene therapy in oncology is to target and modify the genetic factors contributing to cancer development, growth, and resistance to treatment.

Regional Insights

The Americas has a significant landscape in gene therapy owing to rising research and innovation with significant investments in this domain. The gene therapy market has witnessed exponential growth, mainly due to the improved prevalence of chronic diseases, availability of funding for genetic research, a strong presence of industry players, and FDA approvals that significantly impact gene therapy trends. The European region shows considerable growth in the gene therapy sector due to advanced research in gene therapy due to its well-established pharmaceutical companies. The European Union invests heavily in healthcare research, including gene therapy. Countries lead in therapeutic clinical trials, particularly in oncology, cardiovascular, and inherited diseases. The Asia-Pacific region is a rapidly emerging market in the arena of gene therapy. The surge in clinical trials spurred by its burgeoning biotech sector and substantial government funding, fast-track innovative gene therapy research is further fueled by expanded market demand. Overall, the APAC region's growth in gene therapy is driven by a combination of large patient populations, growing healthcare expenditure, and evolving regulatory environments.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Gene Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gene Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, AGC Biologics., Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Applied Genetic Technologies Corporation, Astellas Gene Therapies, Biogen Inc., Bluebird Bio, Inc., Cellectis, Inc., Editas Medicine, Inc., Human Stem Cells Institute, Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Mustang Bio, Novartis AG, Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Shenzhen SiBiono GeneTech Co. Ltd., Spark Therapeutics, Inc., and Uniqure N.V..

Market Segmentation & Coverage

This research report categorizes the Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Antigen Gene Therapy
    • Cancer Gene Therapy
    • Cytokine Gene Therapy
    • Suicide Gene Therapy
    • Tumor Suppressor Gene Therapy
  • Vector Type
    • Non-viral Vectors
    • Viral Vectors
  • Application
    • Cardiovascular Diseases
    • Genetic Diseases
    • Infectious Diseases
    • Neurological Diseases
    • Oncological Disorders
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Gene Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gene Therapy Market?

3. What are the technology trends and regulatory frameworks in the Gene Therapy Market?

4. What is the market share of the leading vendors in the Gene Therapy Market?

5. Which modes and strategic moves are suitable for entering the Gene Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Chronic Diseases and Upsurge in Number of Gene Therapy Treatment Centers
      • 5.1.1.2. Government Support and Ethical Acceptance of Gene Therapy For Treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High Costs Associated with Gene Therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Research & Development in Orphan Diseases and Advancements in Gene Therapy
      • 5.1.3.2. Innovative Payment Models and Favorable Regulatory Approvals
    • 5.1.4. Challenges
      • 5.1.4.1. Potential Harmful Effects and Moral Concerns Regarding New Gene Therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Prevalence of cancer gene therapy for cancer treatment
    • 5.2.2. Vector Type: Significant utilization of viral vector providing higher efficiency in delivering genes into cells
    • 5.2.3. Application: Potential adoption of gene therapy as a revolutionary approach to treating cardiovascular diseases
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Gene Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Antigen Gene Therapy
  • 6.3. Cancer Gene Therapy
  • 6.4. Cytokine Gene Therapy
  • 6.5. Suicide Gene Therapy
  • 6.6. Tumor Suppressor Gene Therapy

7. Gene Therapy Market, by Vector Type

  • 7.1. Introduction
  • 7.2. Non-viral Vectors
  • 7.3. Viral Vectors

8. Gene Therapy Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
  • 8.3. Genetic Diseases
  • 8.4. Infectious Diseases
  • 8.5. Neurological Diseases
  • 8.6. Oncological Disorders

9. Americas Gene Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gene Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gene Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
    • 12.3.2. Laurus to launch Gene Therapy Assets in India
    • 12.3.3. Bluebird bio Lays Gene Therapy Launch Groundwork As Sickle Cell Application Nears

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. GENE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. GENE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENE THERAPY MARKET DYNAMICS
  • FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY ANTIGEN GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY ANTIGEN GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY CANCER GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY CANCER GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY CYTOKINE GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY CYTOKINE GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY SUICIDE GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY SUICIDE GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY TUMOR SUPPRESSOR GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY TUMOR SUPPRESSOR GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENE THERAPY MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. CANADA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 62. CANADA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. MEXICO GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. MEXICO GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. UNITED STATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. UNITED STATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 76. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. AUSTRALIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. AUSTRALIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. CHINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CHINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CHINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. CHINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. INDIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. INDIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. INDIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. INDIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. INDONESIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. INDONESIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. INDONESIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. INDONESIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. JAPAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. JAPAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. JAPAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 114. JAPAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. MALAYSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. MALAYSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. MALAYSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. MALAYSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. PHILIPPINES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. PHILIPPINES GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. SINGAPORE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. SINGAPORE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. SINGAPORE GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. SINGAPORE GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. SOUTH KOREA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. TAIWAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. TAIWAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. TAIWAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. TAIWAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. THAILAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. THAILAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. THAILAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. THAILAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. VIETNAM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. VIETNAM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. VIETNAM GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. VIETNAM GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. DENMARK GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. DENMARK GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. DENMARK GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. DENMARK GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. EGYPT GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. EGYPT GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. EGYPT GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. EGYPT GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. FINLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. FINLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. FINLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. FINLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. FRANCE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. FRANCE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. FRANCE GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. FRANCE GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. GERMANY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. GERMANY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. GERMANY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. GERMANY GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. ISRAEL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. ISRAEL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. ISRAEL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. ISRAEL GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. ITALY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. ITALY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. ITALY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. ITALY GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. NETHERLANDS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. NETHERLANDS GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 212. NETHERLANDS GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. NIGERIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. NIGERIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. NIGERIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. NIGERIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. NORWAY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. NORWAY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. NORWAY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. NORWAY GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. POLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. POLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. POLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. POLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. QATAR GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. QATAR GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. QATAR GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 236. QATAR GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. RUSSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. RUSSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. RUSSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. RUSSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. SPAIN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SPAIN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SPAIN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. SPAIN GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. SWEDEN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. SWEDEN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. SWEDEN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. SWEDEN GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. SWITZERLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. SWITZERLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. SWITZERLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. TURKEY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. TURKEY GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. TURKEY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. TURKEY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. TURKEY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. TURKEY GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 290. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 291. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 292. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023